Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial
…, J Cardona, B Mocherla, V Stosor, I Shawa, P Kumar… - Jama, 2021 - jamanetwork.com
… Dr Kumar reported receiving grants and consulting fees from GlaxoSmithKline, Amgen,
TheraTechnologies, Merck, and Gilead Sciences; and owning stock in GlaxoSmithKline, Johnson …
TheraTechnologies, Merck, and Gilead Sciences; and owning stock in GlaxoSmithKline, Johnson …
[HTML][HTML] Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease
Background & Aims There are no effective and safe treatments for chronic hepatitis C virus (HCV)
infection of patients who have advanced liver disease. Methods In this phase 2, open-…
infection of patients who have advanced liver disease. Methods In this phase 2, open-…
[HTML][HTML] Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection
…, P Yeni, A Lazzarin, B Clotet, PN Kumar… - … England Journal of …, 2008 - Mass Medical Soc
Background We evaluated the efficacy of raltegravir and the development of viral resistance
in two identical trials involving patients who were infected with human immunodeficiency …
in two identical trials involving patients who were infected with human immunodeficiency …
Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia …
…, R Zajdenverg, G Fätkenheuer, DS Berger, PN Kumar… - The Lancet, 2010 - thelancet.com
Background To reduce lipid abnormalities and other side-effects associated with antiretroviral
regimens containing lopinavir-ritonavir, patients might want to switch one or more …
regimens containing lopinavir-ritonavir, patients might want to switch one or more …
Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 …
BENCHMRK-1 and -2 are ongoing double-blind phase III studies of raltegravir in patients
experiencing failure of antiretroviral therapy with triple-class drug-resistant human …
experiencing failure of antiretroviral therapy with triple-class drug-resistant human …
[HTML][HTML] Bamlanivimab plus etesevimab in mild or moderate Covid-19
…, G Huhn, J Cardona, I Shawa, P Kumar… - … England Journal of …, 2021 - Mass Medical Soc
Background Patients with underlying medical conditions are at increased risk for severe
coronavirus disease 2019 (Covid-19). Whereas vaccine-derived immunity develops over time, …
coronavirus disease 2019 (Covid-19). Whereas vaccine-derived immunity develops over time, …
Factors associated with death in critically ill patients with coronavirus disease 2019 in the US
Importance The US is currently an epicenter of the coronavirus disease 2019 (COVID-19)
pandemic, yet few national data are available on patient characteristics, treatment, and …
pandemic, yet few national data are available on patient characteristics, treatment, and …
Association between early treatment with tocilizumab and mortality among critically ill patients with COVID-19
Importance Therapies that improve survival in critically ill patients with coronavirus disease
2019 (COVID-19) are needed. Tocilizumab, a monoclonal antibody against the interleukin 6 …
2019 (COVID-19) are needed. Tocilizumab, a monoclonal antibody against the interleukin 6 …
[HTML][HTML] Raltegravir with optimized background therapy for resistant HIV-1 infection
RT Steigbigel, DA Cooper, PN Kumar… - … England Journal of …, 2008 - Mass Medical Soc
Background Raltegravir (MK-0518) is an inhibitor of human immunodeficiency virus type 1 (HIV-1)
integrase active against HIV-1 susceptible or resistant to older antiretroviral drugs. …
integrase active against HIV-1 susceptible or resistant to older antiretroviral drugs. …
Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease
…, MF Para, TP Flanigan, PN Kumar… - Annals of internal …, 2001 - acpjournals.org
Background: Mortality and morbidity related to AIDS have decreased among HIV-infected
patients taking highly active anti-retroviral therapy (HAART), but previous studies may have …
patients taking highly active anti-retroviral therapy (HAART), but previous studies may have …
